2022
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicHumansLymphoma, T-Cell, CutaneousMycosis FungoidesNeoplasm StagingSezary SyndromeSkin NeoplasmsUnited StatesConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy design
2011
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal Of Clinical Oncology 2011, 29: 2598-2607. PMID: 21576639, PMCID: PMC3422534, DOI: 10.1200/jco.2010.32.0630.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeSézary syndromeMycosis fungoidesClinical trialsEnd pointResponse criteriaUnited States Cutaneous Lymphoma ConsortiumCutaneous T-cell lymphomaCutaneous Lymphoma Task ForceInvestigator-initiated clinical trialsPotential disease manifestationsClinical end pointsEarly mycosis fungoidesT-cell lymphomaUniform stagingCutaneous lymphomasLymph nodesTreatment of cancerHodgkin's lymphomaDisease manifestationsConsensus statementConsensus recommendationsVisceral organsEuropean OrganizationLymphoma
2001
Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas
KNOBLER R, GIRARDI M. Extracorporeal Photochemoimmunotherapy in Cutaneous T Cell Lymphomas. Annals Of The New York Academy Of Sciences 2001, 941: 123-138. PMID: 11594566, DOI: 10.1111/j.1749-6632.2001.tb03716.x.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT cell clonesAutoreactive T cell clonesT-cell lymphomaCell clonesCell lymphomaDisease-causing T cellsPathogenic T cell clonesT cell-mediated disordersClass I Major Histocompatibility Complex PresentationClonotypic T cell receptorCell-mediated disordersTumor-specific antigensMajor histocompatibility complex presentationT cell receptorTypes of cancerUnique antigenic determinantsECP efficacyHost diseaseAllograft rejectionConversion of monocytesSelective immunotherapyClinical trialsFunctional DCsDendritic antigen